We are live on ! Find out more
CNTB

Connect Biopharma Holdings
CNTB

16 hedge funds and large institutions have $11.7M invested in Connect Biopharma Holdings in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $10.9M → $11.7M (+$765K)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

1.01% less ownership

Funds ownership: 19.83% → 18.82% (-1%)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$33.4K
2
Two Sigma Investments
Two Sigma Investments
New York
+$26.4K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$11.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$7.17K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$423K
2
KCM
Kynam Capital Management
New Jersey
-$229K
3
JP Morgan Chase
JP Morgan Chase
New York
-$33.8K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11.4K
5
UBS Group
UBS Group
Switzerland
-$9.34K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$7.9M – – –
BlackRock
2
BlackRock
New York
$1.27M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$735K -$423K -377,519 -37%
UOC
4
UBS O'Connor
Illinois
$670K +$33.4K +29,752 +5%
KCM
5
Kynam Capital Management
New Jersey
$603K -$229K -204,644 -28%
IC
6
Ikarian Capital
Texas
$244K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$108K +$7.17K +6,400 +7%
JP Morgan Chase
8
JP Morgan Chase
New York
$53.7K -$33.8K -30,175 -38%
BFM
9
Boothbay Fund Management
New York
$30.4K – – –
Two Sigma Investments
10
Two Sigma Investments
New York
$26.7K +$26.4K +23,586 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$21.1K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$11.6K -$11.4K -10,200 -49%
RhumbLine Advisers
13
RhumbLine Advisers
Massachusetts
$11K +$11.1K +9,935 New
Fidelity Investments
14
Fidelity Investments
Massachusetts
$26 -$10 -9 -27%
Morgan Stanley
15
Morgan Stanley
New York
$1 – – –
UBS Group
16
UBS Group
Switzerland
– -$9.34K -9,336 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– -$7 -6 -15%
Bank of America
18
Bank of America
North Carolina
– -$2 -2 Closed

CNTB Hedge Fund Activity: Q2 2023 in Review

16 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q2 2023, worth a combined $11.7M — up 7% from $10.9M a quarter earlier.

Fund positioning in CNTB was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 6 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $33.4K. The largest seller was Adage Capital Partners, cutting an estimated $423K.

  • 16 institutional investors held Connect Biopharma Holdings (CNTB) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $11.7M of Connect Biopharma Holdings stock for Q2 2023, up 7% quarter-over-quarter.
  • 2 funds opened new Connect Biopharma Holdings positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest Connect Biopharma Holdings buyer in Q2 2023 was UBS O'Connor, an estimated $33.4K added.
  • The largest Connect Biopharma Holdings seller in Q2 2023 was Adage Capital Partners, an estimated $423K sold.

Based on aggregated 13F filings for Q2 2023.